Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer handbags, luxury face creams and trips to Paris have all fallen victim to ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...

President Trump is likely to embrace the Medicare drug price negotiations that was initiated under the Biden administration, though the president could make some tweaks to put his own spin on it. The ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

Major stock indexes closed higher on Friday, driven by corporate earnings reports from tech firms like Alphabet and Amazon.

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US counterparts.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...